CCNU, vinblastine, and delalutin therapy in renal cell carcinoma

✍ Scribed by Vosika, Gerald J. ;Ryan, Michael J. ;Fortuny, Ignacio A. ;Meyer, Cynthia ;Kiang, David T. ;Theologides, Athanasios ;Kennedy, Byrl J.

• Publisher: John Wiley and Sons
• Year: 1978
• Tongue: English
• Weight: 189 KB
• Volume: 5
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950050114

✦ Synopsis

Abstract

Advanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current study investigated this combination of drugs together with a progestational agent, Delalutin. Seventeen patients with metastatic renal cell carcinoma were treated with CCNU, vinblastine and Delalutin. There were no objective responses. Four patients with stable disease had a mean survival of 18 months compared to 13 patients with progressive disease who had a mean survival of 5 months. The survival of the four patients with stable disease was in large part due to the slowly progressive natural history of their disease.